The Patient Transition Program
The Patient Transition Program in Princeton, NJ, offers support for individuals transitioning to HYRIMOZ, a biosimilar to Humira, which is FDA-approved for various conditions including rheumatoid arthritis, Crohn's disease, and psoriasis. The program provides financial assistance, injection training, and access to Nurse Ambassadors to ensure a smooth transition for patients.
HYRIMOZ has been prescribed to over 300,000 people worldwide since its availability outside the United States in 2018, demonstrating its effectiveness and safety comparable to Humira. The program also includes a one-time reimbursement for eligible patients switching from Humira, along with a co-pay card that may significantly reduce out-of-pocket costs for the medication.
Generated from the website



